Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Visualizing dual downregulation of IGF-1R and VEGF by Hsp90 inhibition effect in triple negative breast cancer

Terwisscha van Scheltinga , Anton G.T. and Berghuis, Paul and Nienhuis, Hilde H and Schröder, Carolien P (2014) Visualizing dual downregulation of IGF-1R and VEGF by Hsp90 inhibition effect in triple negative breast cancer. European Journal of Cancer, 50 (14). pp. 2508-2516. ISSN 09598049

Abstract

Purpose Triple negative breast cancer (TNBC) is biologically characterized by heterogeneous presence of molecular pathways underlying it. Insulin-like growth factor receptor-1 (IGF-1R) expression and vascular endothelial growth factor-A (VEGF-A) have been identified as key factors in these pathways in TNBC. In this study, we aimed at in vivo PET imaging the effect of heat shock protein (Hsp) 90 inhibition by means of NVP-AUY922 on these pathways, with zirconium-89 (89Zr) labeled antibodies targeting IGF-1R and VEGF.
Experimental design In vitro NVP-AUY922 effects on cellular IGF-1R expression and VEGF-A secretion were determined in MCF-7 and MDA-MB-231 cell lines. Moreover human TNBC bearing MDA-MB-231 mice received 50 mg/kg NVP-AUY922 or vehicle q3d intraperitoneally for 21 days. PET scans with 89Zr-MAB391 and 89Zr-bevacizumab for visualization of IGF-1R and VEGF were performed before and during treatment. Ex vivo biodistribution and correlative tissue analyses were performed.
Results NVP-AUY922 treatment reduced IGF-1R expression and VEGF-A excretion in both cell lines. Hsp90 inhibition lowered tumor uptake on 89Zr-MAB391-PET by 37.3% (P < 0.01) and on 89Zr-bevacizumab-PET by 44.4% (P < 0.01). This was confirmed by ex vivo biodistribution with a reduction of 41.3 % injected dose (ID)/g for 89Zr-MAB391 and 37.8 %ID/g for 89Zr-bevacizumab, while no differences were observed for other tissues. This coincided with reduced IGF-1R expression and mean vessel density in the NVP-AUY922 treated tumors.
Conclusion 89Zr-MAB391 and 89Zr-bevacizumab PET reflect effect of Hsp90 inhibitors and can therefore potentially be used to monitor therapeutic effects of Hsp90 inhibitor therapy in TNBC.

Item Type: Article
Date Deposited: 26 Apr 2016 23:46
Last Modified: 26 Apr 2016 23:46
URI: https://oak.novartis.com/id/eprint/8873

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.